Top Cannabis Investment News, Member Posts, Cannabis Investment Daily Indices and more!

1yr ago Cannabis greenmarketreport Views: 362

-

The Daily Hit is a recap of cannabis business news for August 31, 2022.

ON THE SITE

Detroit to Reopen Adult Use Cannabis Applications After Court Ruling

The city of Detroit plans to reopen its adult-use marijuana application process this week after a Wayne County Circuit Court judge dismissed two lawsuits Tuesday that challenged the city’s ordinance. The city will award 60 dispensary licenses during the first phase with another 100 planned in subsequent licensing phases. Read more here.

Arkansas AG Wades Into Court Fight Over Adult-Use Marijuana Ballot Measure

An ongoing court battle over a proposed ballot measure in Arkansas to legalize recreational marijuana has now corralled the state attorney general’s office into the case. In a court filing this week, the state’s top law enforcement officer called the initiative “misleading.” Read more here.

Recreational Marijuana ‘Unlikely’ To Be On Oklahoma Ballot After State Supreme Court Ruling

The Oklahoma state Supreme Court declined a request by a political campaign to order election officials to print ballots with a still-pending recreational marijuana legalization ballot question on them, thus reducing the odds that residents will get to vote on adult-use legalization this year. Read more here.

Emerald Health Bids Cannabis Farewell

Emerald Health Therapeutics, Inc. (CSE: EMH) (OTCQB: EMHTF) reported its financial results for the year ending June 30, 2022, as it closes the curtains on the cannabis industry. Emerald Health shareholders approved an agreement with Skye Bioscience, a San Diego-based pharmaceutical company developing proprietary, synthetic cannabinoid derivatives. The deal is expected to close by mid-October. Read more here.

Red White & Bloom Makes Progress In Sales, But At A High Cost

Red White & Bloom Brands attributed its increase in sales volume to vape product sales generated by House of Platinum or Platinum Vape (PV) PV California, PV Michigan, the added sales from the closing of the PharmaCo transaction in February of 2022, and cannabis product sales generated by RWB Florida. But that increase was offset by lower prices. Read more here.

Evogene Cannabis Revenue Rises In Israeli Market

Rising sales of Caconic medical cannabis products helped boost Rehovot, Israel-based Evogene Ltd.’s balance sheet for the second quarter ending June 30, 2022. Read more here.

IN OTHER NEWS

Willow Biosciences Provides CBG Update

Willow Biosciences completed the initial phases of technology transfer with a second Contract Development and Manufacturing Organization and anticipates running its first commercial batches of CBG products in the first half of 2023. Read more here.

Leviathan Completes Sale of Woodstock Biomed

Leviathan Natural Products completed the sale of its 100% interest in Woodstock Biomed for total consideration of $5 million. Read more here.

The Daily Hit: August 31, 2022 on Green Market Report.


Today's Cannabis Investment Headlines:

Log In for More
Access Over 250K+ Industry Headlines, Posts and Updates
Not a member yet?

Join AlphaMaven

The Premier Alternative Investment
Research and Due Diligence Platform for Investors

Free Membership for Qualified Investors and Industry Participants
  • Easily Customize Content to Match Your Investment Preferences
  • Breaking News 24/7/365
  • Daily Newsletter & Indices
  • Alternative Investment Listings & LeaderBoards
  • Industry Research, Due Diligence, Videos, Webinars, Events, Press Releases, Market Commentary, Newsletters, Fact Sheets, Presentations, Investment Mandates, Video PitchBooks & More!
  • Company Directory
  • Contact Directory
  • Member Posts & Publications
  • Alpha University Video Series to Expand Investor Knowledge
  • AUM Accelerator Program (designed for investment managers)
  • Over 450K+ Industry Headlines, Posts and Updates
ALL ALPHAMAVEN CONTENT IS FOR INFORMATIONAL PURPOSES ONLY. CONTENT POSTED BY MEMBERS DOES NOT NECESSARILY REFLECT THE OPINION OR BELIEFS OF ALPHAMAVEN AND HAS NOT ALWAYS BEEN INDEPENDENTLY VERIFIED BY ALPHAMAVEN. PAST PERFORMANCE IS NOT INDICATIVE OF FUTURE RESULTS. THIS IS NOT A SOLICITATION FOR INVESTMENT. THE MATERIAL PROVIDED HEREIN IS FOR INFORMATIONAL PURPOSES ONLY. IT DOES NOT CONSTITUTE AN OFFER TO SELL OR A SOLICITATION OF AN OFFER TO BUY ANY INTERESTS OF ANY FUND OR ANY OTHER SECURITIES. ANY SUCH OFFERINGS CAN BE MADE ONLY IN ACCORDANCE WITH THE TERMS AND CONDITIONS SET FORTH IN THE INVESTMENT'S PRIVATE PLACEMENT MEMORANDUM. PRIOR TO INVESTING, INVESTORS ARE STRONGLY URGED TO REVIEW CAREFULLY THE PRIVATE PLACEMENT MEMORANDUM (INCLUDING THE RISK FACTORS DESCRIBED THEREIN), THE LIMITED PARTNERSHIP AGREEMENT AND THE SUBSCRIPTION DOCUMENTS, TO ASK SUCH QUESTIONS OF THE INVESTMENT MANAGER AS THEY DEEM APPROPRIATE, AND TO DISCUSS ANY PROSPECTIVE INVESTMENT IN THE FUND WITH THEIR LEGAL AND TAX ADVISERS IN ORDER TO MAKE AN INDEPENDENT DETERMINATION OF THE SUITABILITY AND CONSEQUENCES OF AN INVESTMENT.